Mylod%252525252525252520at

# Mylod%252525252525252520at (Mylod) ## Overview Mylod (often confused with *Mylotarg* or *Mylanta*) is not a recognized generic drug name. **If searching for Mylotarg (Gemtuzumab ozogamicin):** It is a CD33-directed antibody-drug conjugate (ADC) used in AML. **If searching for an over-the-counter antacid (Mylanta):** It is a combination of aluminum hydroxide, magnesium hydroxide, and simethicone. *Note: As "Mylod" is not a standard pharmaceutical nomenclature, confirm the exact medication name, indication, and spelling with the prescribing clinician immediately.* ## Primary Indications Assuming **Mylotarg (Gemtuzumab ozogamicin)**: * Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients ≥1 month. * Relapsed or refractory CD33-positive AML. ## Adult Dosing * **Newly Diagnosed AML:** 3 mg/m² (up to a maximum dose of 4.5 mg per single dose) on days 1, 4, and 7 in combination with daunorubicin and cytarabine. * **Relapsed/Refractory AML:** 3 mg/m² (up to 4.5 mg) on days 1, 4, and 7 as a single agent. ## Pediatric Dosing * **≥1 Month:** Dosing is based on body surface area (BSA). * BSA ≥0.6 m²: 3 mg/m² (max 4.5 mg/dose) on days 1, 4, and 7. * BSA <0.6 m²: 0.1 mg/kg on days 1, 4, and 7. ## Dose Adjustments * **Hepatic Impairment:** Avoid in patients with severe hepatic impairment (total bilirubin >2x ULN, or AST/ALT >2.5x ULN). * **Infusion Rate:** If an infusion reaction occurs, interrupt or slow the infusion rate. ## Contraindications * Hypersensitivity to gemtuzumab ozogamicin or any component of the formulation. * Known severe hepatic impairment (as defined above). ## Adverse Effects * **Hepatotoxicity:** Includes sinusoidal obstruction syndrome (SOS/VOD), which is life-threatening. * **Myelosuppression:** Severe neutropenia, thrombocytopenia, and anemia. * **Infusion-related reactions:** Chills, fever, tachycardia, hypotension. * **Infections:** Significant risk of opportunistic infections due to immunosuppression. ## Key Drug Interactions * **Hepatotoxic Agents:** Risk of additive liver toxicity; avoid or monitor closely. * **Live Vaccines:** Avoid live vaccines; immune response may be impaired. ## Monitoring * **Liver Function Tests:** Monitor bilirubin, GGT, ALP, and transaminases prior to each dose and throughout treatment. * **CBC:** Monitor blood counts frequently for signs of myelosuppression. * **Clinical:** Monitor for signs of SOS/VOD (weight gain, hepatomegaly, ascites, jaundice). ## Clinical Pearls * **Premedication:** Always administer corticosteroids, antihistamines, and acetaminophen prior to each infusion to mitigate infusion-related reactions. * **VOD Risk:** The risk of SOS is increased in patients undergoing hematopoietic stem cell transplantation (HSCT) post-therapy. * **Medication Name Error:** If this query was intended for a different medication, please verify the spelling, as "Mylod" is not a standard drug product. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by institution. Always verify the drug name, dose, and administration instructions with current, reputable tertiary clinical databases (e.g., Lexicomp, UpToDate) and official FDA/EMA prescribing information before initiating therapy.